Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYB003 in Healthy Volunteers and MDD
NCT05385783Phase 2Completed
- Sponsor
- Cybin Inc.
- Start
- Aug 2022
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of CYB003 in major depressive disorder (MDD), sponsored by Cybin Inc.. Started Aug 2022; status: completed.
02
Drugs
CYB003
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05385783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05385783.